Mark is editor-in-chief and founder of BioPub, a small-cap biotech investing situations analysis website with a global following. He graduated summa cum laude from University of North Carolina with a chemistry and was a rare junior-year inductee into Phi Beta Kappa.
In the NIH-sponsored Medical Scientist Training Program at Duke University, he earned an MD with junior election to Alpha Omega Alpha and a PhD in biochemistry and cell biology with special distinction.
He trained in categorical internal medicine at Duke, completed post-doctoral work in distintegrins at National Taiwan University (Taipei), and returned to Duke for research and clinical fellowships in gastroenterology and transplant hepatology.
After serving on the faculties of Duke, where he was awarded the medical center’s highes teaching honor, and later University of Texas MD Anderson Cancer Center (Houston), where he was elected to the faculty senate, and UT Health Science Center in Houston, he established an independent freestanding hepatology clinic and clinical research institute, leading clinical trials for a large number of pharma companies and speaking nationally on interferon therapeutics for virus hepatitis as a key opinion leader for many years.
He authored more than three dozen peer-reviewed publications and chapters, over 100 abstracts, and was elected Fellow of the American College of Physicians in 2002.
With an impressive record of success in biotech investing and analysis, and the growing success of BioPub, he decided to devote all energies to guiding biotech investors, analyzing investing situations, and serving as a consultant to the biotech industry.